不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
B 细胞耗竭患者迁延性 2019 冠状病毒病（COVID-19）经瑞德西韦和恢复期血浆治疗后的持续应答
英文原题：Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).
查看英文原题
Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
我们提供了一名因滤泡性淋巴瘤接受奥妥珠单抗治疗、导致B细胞耗竭的患者详细临床、病毒学和免疫学数据，该患者患有迁延性2019冠状病毒病（COVID-19）和病毒血症。经过2个疗程的瑞德西韦治疗及随后的恢复期血浆治疗后，实现了持续应答。免疫功能低下的患者可能需要联合和延长的抗病毒治疗方案。
展开英文摘要原文
We provide detailed clinical, virological, and immunological data of a B-cell-depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.
论文信息
- 作者
- Malsy J、Veletzky L、Heide J、Hennigs A、Gil-Ibanez I、Stein A、Lütgehetmann M、Rosien U
- 单位
- Department of Medicine, Gastroenterology, and Hepatology, Sections of Infectious Diseases and Tropical Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.Germany
- 文献类型
- 非美国政府资助研究
- 期刊
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America2021 Dec 6
- 原文标识
- PubMed 33103195 · DOI 10.1093/cid/ciaa1637
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →